摘要
目的：研究新辅助放疗对肺鳞状细胞癌（ LSCC）组织中CD44v6表达的影响及其临床意义。方法收集2013年5月至2015年1月于我院胸外科行肺穿刺活检证实为LSCC的患者共50例，其中20例Ⅲa期患者均行术前新辅助放疗，结束新辅助治疗后行外科手术，免疫组化检测穿刺活检及手术切除标本中CD44v6表达，分析CD44v6蛋白表达与患者临床病理资料间的相关性。结果穿刺活检肿瘤组织进行CD44v6免疫组化染色，CD44v6蛋白阳性表达率高达72％（36／50）；CD44v6蛋白的阳性表达与肿瘤淋巴结转移（χ2＝3．964，P＝0．046）及高TNM分期（Ⅲ＋Ⅳ期）（χ2＝4．276，P＝0．039）显著相关；与放疗前相比，20例术前新辅助放疗患者新辅助放疗后肿瘤组织中CD44v6蛋白的阳性表达显著降低（7．23±1．45与11．42±1．31，t＝2．524，P＝0．025）。结论 CD44v6在LSCC组织中的阳性表达与肿瘤恶性临床病理特征有关，术前行新辅助放疗可能通过下调CD44v6的表达来改善LSCC患者预后。
Objective To investigate the effect and clinical significance of neoadjuvant radiotherapy for the expression of CD44v6 in lung squamous cell carcinoma tissues. Methods Fifty cases lung squamous cell carcinoma patients confirmed by aspiration biopsy from May 2013 to January 2015 were collected in Yangquan Coal Mine Group Genernal Hospital,including 20 cases of patients with stageⅢA were treated with neoadjuvant radiotherapy before surgery,and then performed surgery after neoadjuvant therapy. The expression of CD44v6 was detected by immunohistochemistry. The correlation between CD44v6 and clinicopathological features was analyzed by chi-square test. Results Immunohistochemical staining of CD44v6 was performed in tumor tissue of puncture biopsy, the positive rate expression of CD44v6 was 72%（ 36/50 ） , it was associated with lymphatic metastasis（χ2 =3. 964, P=0. 046 ） and advanced TNM stage （Ⅲ＋Ⅳstage ） （χ2 =4. 276, P=0. 039 ） . The positive expression of CD44v6 protein in tumor tissue was significantly decreased in 20 patients with neoadjuvant radiotherapy compared with before radiotherapy（7. 23±1. 45 vs. 11. 42±1. 31,t=2. 524,P=0. 025）. Conclusion Positive expression of CD44v6 in human lung squamous cell carcinoma is related to the malignant clinicopathological features. Neoadjuvant radiotherapy before operation may improve prognosis via down？regulating CD44v6 expression.
出处
《中国综合临床》
2016年第7期633-636,共4页
Clinical Medicine of China
关键词
新辅助放疗
肺鳞状细胞癌
CD44V6
表达
Neoadjuvant radiotherapy
Lung squamous cell carcinoma
CD44v6
Expression
